Loading
Jubilant Pharmova Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest was filed 01 Oct 2025.
Jubilant Pharmova Limited: what insiders have been doing
Every trade that managers of Jubilant Pharmova Limited disclose to SEBI (PIT + SAST) is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 18 October 2026, the company's managers filed 2 filings, from 2 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Compared with its exchange (1,985 companies, median 4 filings), a count of 2 filings is below the norm. Our records for Jubilant Pharmova Limited go back to 2022, with 30 purchases and no sales on the open market in total.
No insider has bought Jubilant Pharmova Limited shares on the open market in the past twelve months.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.
Insider Decl.
43
Thresholds
n/a
Buy Volume
€6M
30 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJubilant Employees Welfare Trust5 buys
Since the insiders bought
- -4.1%Entry ₹1,119.40 · Close at T+90 ₹1,073.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Jubilant Pharmova Limited Buy (bullish), based on 2 analysts. Average price target: ₹1,088.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 14,139 of 24,148 companies
46.5
score / 100
Value39
Quality54
FCF yld-1.5%
Earn yld2.7%
EV/EBITDA14.7x
ROE6.0%
Gross mgn64%
Net mgn4.8%
Debt/EBITDA2.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹936.60
Analyst consensus
2 analystsBuy
₹850.00Target ₹1,088.50(+16%)₹1,327.00
Income statement
Revenue₹82.3B
Gross profit₹52.3B64% margin
EBITDA₹12.6B15% margin
Net income₹4B4.1% margin
Valuation
PER (trailing)42.2x
PER (forward)18.5x
P/Book2.1x
Beta0.47
Balance sheet & cash
Market cap₹148.3B
Total debt₹36.1B
Free Cash Flow-₹2.2B
Debt / Equity51%
Profitability & ownership
ROE6.0%
ROA3.6%
% insiders56.2%
% institutions24.0%
Last declaration on 30 June 2026
Declarations43 total
450,000 shares-CreationSEBI:89b1461793fd39b28ba8185af82f70741661d37f
11,304 shares@ ₹820.851.3% of flowEquity SharesSEBI:87d488d3b5595d70fa1fcf8338df41bb9cd68094
11,319 shares@ ₹1,076.72671.7% of flowEquity SharesSEBI:803b6e543586d00493a9ad7c8110dfd878852c74
Canonical exit: 29 Dec 2025 (T+90)
57,181 shares@ ₹1,056.37198.4% of flowEquity SharesSEBI:4d627390d0a80134fc168da6d6ab4dd96c9cfd27
Canonical exit: 28 Dec 2025 (T+90)
20,000 shares@ ₹1,039.252.9% of flowEquity SharesSEBI:cc14cdfd78c0546b9a12eab739ce6ab01a65447f
Canonical exit: 25 Dec 2025 (T+90)
50,676 shares@ ₹1,069.65747.6% of flowEquity SharesSEBI:5857c24f13a5e4c7805945e5825e36db93a83127
Canonical exit: 24 Dec 2025 (T+90)
35,000 shares@ ₹1,107.83455.4% of flowEquity SharesSEBI:cc916e3cd26f11b645106ff32a92875d3f87cca3
Canonical exit: 18 Dec 2025 (T+90)
2,050,000 shares@ ₹1,077.50100.0% of flowEquity SharesSEBI:e13e427158dbace590815e22ae6d261db65df296
2,050,000 shares@ ₹1,077.5074.3% of flowEquity SharesSEBI:0818f7b49525c408495bc445b206ce571cada79d
700,000 shares@ ₹1,060.0025.7% of flowEquity SharesSEBI:eb57fbf8213296e9d9b966450f811ecc43a89329
1,962,434 shares@ ₹1,060.372100.0% of flowEquity SharesSEBI:6cc35fd4c09808c90fe3731eff3cba7e8362f500
2,116,000 shares@ ₹1,060.00100.0% of flowEquity SharesSEBI:8976d12d513dad3edac892e4c2892473a84f998f
10,028 shares@ ₹1,214.31781.9% of flowEquity SharesSEBI:7349d04468495933db47797bef193b32c98bc7ba
Canonical exit: 16 Dec 2024 (T+90)
36,025 shares@ ₹1,215.45226.8% of flowEquity SharesSEBI:1bce5b1abdc6fa3dc1c83adbd560aad161189c97
Canonical exit: 16 Dec 2024 (T+90)
3,542 shares@ ₹1,219.59990.7% of flowEquity SharesSEBI:79aa095f2cdd9b4c99d62aae0a8178fde6edcfa4
6,877 shares@ ₹1,191.001.3% of flowEquity SharesSEBI:68eb6085db672cdfbafc116ba6517d3f5d0e4459
18,045 shares@ ₹937.702.6% of flowEquity SharesSEBI:09c6f28f73b5d1b315f93cacced4408c1b8ea5b9
39,147 shares@ ₹916.955.6% of flowEquity SharesSEBI:7974d1d39d6a5fc8c664b508750dad8a691ec2b7
1,576 shares@ ₹902.6999100.0% of flowEquity SharesSEBI:29c4597a1867901c21f0e3098d76a3520c2222e8
22,858 shares@ ₹862.953.1% of flowEquity SharesSEBI:c550d11ccba991f606b5ab7c95c629044cefbea2
14,327 shares@ ₹397.0680.9% of flowEquity SharesSEBI:be999d2fb0da3966b9a2c812dfcc36abfdda2a41
Canonical exit: 21 Sept 2023 (T+90)
33,673 shares@ ₹397.36362.2% of flowEquity SharesSEBI:e27de47b20331d6be42e351440cd6a234cfaf7b4
Canonical exit: 21 Sept 2023 (T+90)
15,522 shares@ ₹405.90081.0% of flowEquity SharesSEBI:e3e4d4c8ee6584b68ec032fdea4b23fe56b99045
Canonical exit: 19 Sept 2023 (T+90)
84,478 shares@ ₹406.19725.5% of flowEquity SharesSEBI:70894e9bedf220d0bd7eb3ce9795945e5aaaca77
Canonical exit: 19 Sept 2023 (T+90)
20,680 shares@ ₹413.1631.4% of flowEquity SharesSEBI:1570c23704d7a5e323b9613b9a86dc0a2942e797
Canonical exit: 17 Sept 2023 (T+90)
25 of 43 declarations
About Jubilant Pharmova Limited
Jubilant Pharmova Limited is a company focused on health and pharmaceuticals, providing pharmaceutical solutions and research services. It is listed on the XBOM market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
